[HTML][HTML] A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant …
MP Kolinsky, P Rescigno, D Bianchini, Z Zafeiriou… - Annals of oncology, 2020 - Elsevier
Background Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate …
MP Kolinsky, P Rescigno… - Annals of oncology …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate …
MP Kolinsky, P Rescigno, D Bianchini… - Annals of Oncology …, 2020 - europepmc.org
Background Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
[HTML][HTML] A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant …
MP Kolinsky, P Rescigno, D Bianchini… - Annals of …, 2020 - annalsofoncology.org
Background Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate …
MP Kolinsky, P Rescigno, D Bianchini, Z Zafeiriou… - 2020 - repository.icr.ac.uk
BACKGROUND: Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase
and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic …
and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic …
[PDF][PDF] A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration resistant …
MP Kolinsky, P Rescigno, D Bianchini, Z Zafeiriou… - core.ac.uk
Background: Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate …
MP Kolinsky, P Rescigno, D Bianchini… - Annals of …, 2020 - pure.johnshopkins.edu
Background: Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
[PDF][PDF] A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant …
MP Kolinsky, P Rescigno, D Bianchini, Z Zafeiriou… - 2020 - repository.ubn.ru.nl
BACKGROUND: Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase
and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic …
and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic …
[HTML][HTML] A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant …
MP Kolinsky, P Rescigno, D Bianchini… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …
[引用][C] A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant …
MP Kolinsky, P Rescigno, D Bianchini, Z Zafeiriou… - Annals of …, 2020 - cir.nii.ac.jp
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363
(capivasertib) in patients with metastatic castration-resistant prostate cancer | CiNii Research …
(capivasertib) in patients with metastatic castration-resistant prostate cancer | CiNii Research …